Welcome to LookChem.com Sign In|Join Free

CAS

  • or

845616-57-1

Post Buying Request

845616-57-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

845616-57-1 Usage

General Description

2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine is a chemical compound with potential pharmacological properties. It contains a piperazine ring and a pyrimidine ring, and is substituted with a benzyl group and a trifluoromethyl group. 2-(4-Benzylpiperazin-1-yl)-5-trifluoromethylpyrimidine has been studied for its potential as an antipsychotic or antidepressant agent, as well as for its potential use in cancer treatment. It may also have potential applications in the field of medicinal chemistry for the development of new drugs. Further research is needed to fully understand the properties and potential uses of 2-(4-Benzylpiperazin-1-yl)-5-trifluMethylpyrimidine.

Check Digit Verification of cas no

The CAS Registry Mumber 845616-57-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,6,1 and 6 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 845616-57:
(8*8)+(7*4)+(6*5)+(5*6)+(4*1)+(3*6)+(2*5)+(1*7)=191
191 % 10 = 1
So 845616-57-1 is a valid CAS Registry Number.

845616-57-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(4-benzylpiperazin-1-yl)-5-(trifluoromethyl)pyrimidine

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:845616-57-1 SDS

845616-57-1Downstream Products

845616-57-1Relevant articles and documents

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

Pinard, Emmanuel,Alanine, Alexander,Alberati, Daniela,Bender, Markus,Borroni, Edilio,Bourdeaux, Patrick,Brom, Virginie,Burner, Serge,Fischer, Holger,Hainzl, Dominik,Halm, Remy,Hauser, Nicole,Jolidon, Synese,Lengyel, Judith,Marty, Hans-Peter,Meyer, Thierry,Moreau, Jean-Luc,Mory, Roland,Narquizian, Robert,Nettekoven, Mathias,Norcross, Roger D.,Puellmann, Bernd,Schmid, Philipp,Schmitt, Sebastien,Stalder, Henri,Wermuth, Roger,Wettstein, Joseph G.,Zimmerli, Daniel

supporting information; experimental part, p. 4603 - 4614 (2010/09/17)

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.

Substituted acylpiperazine derivatives

-

Page/Page column 22, (2008/06/13)

The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

BENZOYL-PIPERAZINE DERIVATIVES

-

Page/Page column 28, (2008/06/13)

The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 845616-57-1